<DOC>
	<DOC>NCT01808118</DOC>
	<brief_summary>This is a Multicenter, randomized, double-blind study in subjects with moderate to severe non-radiographic Axial Spondyloarthritis. There is a 28-week open-label period followed by a 40-week double-blind, placebo-controlled period for subjects who meet the randomization criteria. Subjects who flare during the double-blind period will have an opportunity to receive at least 12-weeks of rescue therapy.</brief_summary>
	<brief_title>Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult subjects with inadequate response to &gt;/= 2 nonsteroidal antiinflammatories (NSAIDs) Subject with axial SpA fulfilling the Assessment of Spondyloarthritis international Society (ASAS) axial SpA classification criteria Subject with evidence of active inflammation in the sacroiliac (SI) joints or spine on MRI, or elevated hsCRP Negative TB screening assessment Ability to administer subcutaneous injections General good health otherwise Prior antiTumor Necrosis Factor (TNF) therapy; biologic therapy with a potential therapeutic impact on SpA or treated with an investigational drug of chemical or biologic nature within 30 days or 5 halflives of baseline. Fulfillment of the radiographic criterion of the modified New York criteria for Ankylosing Spondylitis Recent infection requiring treatment Significant medical events or conditions that may put patients at risk for participation Female subjects who are pregnant or breastfeeding or considering becoming pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Spondylarthropathy</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Spinal Diseases</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Ankylosing Spondyloarthritis</keyword>
	<keyword>Spondylitis</keyword>
</DOC>